NRC:NSD-National Research Corp (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 39.4

Change

-0.30 (-0.76)%

Market Cap

USD 0.95B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
VEEV Veeva Systems Inc Class A

+1.82 (+0.91%)

USD 32.00B
SOLV Solventum Corp.

+2.60 (+4.21%)

USD 11.73B
DOCS Doximity Inc

+0.23 (+0.97%)

USD 4.83B
EVH Evolent Health Inc

-0.67 (-2.37%)

USD 3.36B
TDOC Teladoc Inc

-0.32 (-2.40%)

USD 2.20B
AGTI Agiliti Inc

+0.01 (+0.10%)

USD 1.37B
PHR Phreesia Inc

+0.15 (+0.73%)

USD 1.30B
SLP Simulations Plus Inc

-0.96 (-2.10%)

USD 0.88B
MPLN MultiPlan Corporation

N/A

USD 0.43B
AMWL American Well Corp

-0.01 (-2.13%)

USD 0.16B

ETFs Containing NRC

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.40% 64% D 30% F
Dividend Return 0.30% 100% F 16% F
Total Return -0.10% 64% D 27% F
Trailing 12 Months  
Capital Gain -11.96% 73% C 16% F
Dividend Return 3.58% 100% F 52% F
Total Return -8.38% 73% C 16% F
Trailing 5 Years  
Capital Gain 2.07% 50% F 46% F
Dividend Return 9.64% 100% F 36% F
Total Return 11.71% 50% F 40% F
Average Annual (5 Year Horizon)  
Capital Gain -5.49% 55% F 33% F
Dividend Return -4.00% 57% F 33% F
Total Return 1.48% 67% D+ 37% F
Risk Return Profile  
Volatility (Standard Deviation) 17.71% 95% A 79% B-
Risk Adjusted Return -22.62% 53% F 30% F
Market Capitalization 0.95B 45% F 55% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector